SCM
KROS icon

Soleus Capital Management’s Keros Therapeutics KROS Stock Holding History

Soleus Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-224,600
Closed -$13M – 98
2024
Q3 		$13M Buy
224,600
+3,000
+1% +$148K 1.01% 34
2024
Q2 		$10.1M Sell
221,600
-52,000
-19% -$2.79M 0.89% 37
2024
Q1 		$18.1M Buy
+273,600
New +$16.2M 1.34% 21
2023
Q4 		– Sell
-12,700
Closed -$405K – 92
2023
Q3 		$405K Sell
12,700
-58,100
-82% -$2.17M 0.04% 91
2023
Q2 		$2.84M Sell
70,800
-51,516
-42% -$2.26M 0.32% 63
2023
Q1 		$5.22M Sell
122,316
-110,800
-48% -$5.6M 0.54% 50
2022
Q4 		$11.2M Buy
233,116
+87,116
+60% +$4.07M 1.61% 24
2022
Q3 		$5.49M Buy
+146,000
New +$5.06M 0.75% 39

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Soleus Capital Management's KROS Position: Q4 2024 in Review

Soleus Capital Management sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 224,600 shares — an estimated $13M sold.

Soleus Capital Management first reported a position in KROS in Q3 2022 and held it in 8 quarters. The position peaked at $18.1M in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • Soleus Capital Management reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Soleus Capital Management sold 224,600 Keros Therapeutics shares in Q4 2024, an estimated $13M.
  • Soleus Capital Management first reported a position in Keros Therapeutics in Q3 2022 and held it in 8 quarters.
  • Soleus Capital Management's Keros Therapeutics position peaked at $18.1M in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.